This page is general information, not medical advice. Your own doctor or care team is the right source for questions about your skin, diagnosis or treatment.
The word early-stage is a broad description. It does not replace the exact stage in a clinical record. Melanoma in situ and invasive skin melanomas have different descriptions, and findings within a stage can also differ. A general outline can explain the terms without assigning a stage from a reader's report.
This page describes the categories national agencies discuss. It does not say which procedure or treatment applies to any particular person. The stage, the location of the melanoma, other findings and the person's wider health all form part of the clinical conversation.
How the findings become a stage
The American Cancer Society's staging explanation describes TNM: information about the primary tumor, nearby lymph nodes and spread to distant parts of the body. The primary tumor is the original melanoma. Its thickness and whether the surface is ulcerated contribute to the tumor description.
Breslow thickness measures the depth of melanoma into the skin. Ulceration means a break in the surface over it. These findings come from the tissue examination and are different from simply measuring the width of the visible spot.
The Society distinguishes a clinical stage, based on examinations, biopsy and any imaging, from a pathological stage that may include further surgical findings. Additional tissue can sometimes change the stage description. The page on reading a pathology report explains the report terms behind that assessment.
Staging is not based on how painful a spot was, how worried someone feels, or how many appointments have occurred. It is a formal way of combining specific findings. Your care team can explain which information established the stage and whether any part of the assessment is still pending.
The early-stage outline
In the American Cancer Society's outline, stage 0 is melanoma in situ. The abnormal cells remain in the epidermis, the outer skin layer, without extension deeper into the skin. There are no signs of nearby-node or distant spread in that stage description.
Stages I and II describe melanoma that has grown into the skin. The primary tumor's thickness and ulceration distinguish the stage groups and their subdivisions. Both groups have no signs of spread to nearby lymph nodes or distant parts of the body in the staging description.
The letters that accompany a stage supply further detail. They do not explain a particular person's outlook by themselves. A letter, a thickness measurement or a margin finding is read within the full staging assessment. This outline deliberately leaves the numerical thresholds to the care team's explanation of the actual report.
How surgery is described
The National Cancer Institute's patient summary describes surgery for melanoma in situ and stages I and II. Removal includes the melanoma or abnormal area and some normal tissue around it. A wide local excision is this removal with a surrounding margin. Your care team can explain which, if any, of these categories apply to you.
The American Cancer Society's surgery guide distinguishes wide excision from the earlier diagnostic biopsy. An excisional biopsy removes an abnormal area to establish the diagnosis. Wider removal after diagnosis has a different purpose and uses the known tissue findings to inform the procedure.
A margin is the edge of the removed tissue. The sample is examined in the laboratory to assess that edge. The Society explains that the thickness and location of the melanoma affect the surgical margin considered. This page provides no margin measurements or instructions about the extent of surgery.
The treatment description and the laboratory description refer to different parts of care. The surgeon removes tissue; the pathologist examines it. A clear explanation can connect the proposed procedure with the findings already known and the information the removed tissue may add.
When node assessment enters the discussion
The NCI summary includes lymph node mapping and sentinel lymph node biopsy in descriptions of some early-stage care. A sentinel node receives drainage from the primary tumor area. Its examination looks for microscopic cancer cells, even when a node is not enlarged on an examination.
The American Cancer Society discusses sentinel-node biopsy in relation to the melanoma's thickness and other features. A discussion about the test does not establish that a node contains melanoma. If cancer is found in a nearby node, the stage description changes. Your care team can explain the question the test would address and which, if any, procedures apply to you.
The separate page on sentinel lymph node biopsy describes mapping, tissue examination, possible harms and research. It is a staging explanation, rather than a recommendation for a test.
Treatment after surgery and follow-up
The American Cancer Society's stage-based treatment guide discusses additional treatment after surgery for some early-stage melanomas, depending on the clinical findings. It describes immune checkpoint inhibitors, a type of immune-based treatment, and, for cancers with relevant gene changes, targeted therapy categories. The NCI also describes immunotherapy, treatment working through the immune system, after surgery for some stage II melanoma. Your care team can explain which, if any, apply to you.
Treatment given after the main procedure is called adjuvant treatment. The term describes its place in a plan; it is not a separate stage. Agency discussions of these treatments describe particular circumstances and do not mean every early-stage melanoma has the same treatment after surgery.
The agencies also describe follow-up. Its purpose includes reviewing health and watching for changes after treatment. The guide to care after melanoma treatment explains the general role of appointments, skin checks and records. The actual follow-up plan, including any tests, comes from the clinical team.